Breast Cancer: Combination Therapy Slows Tumor Growth
- CHICAGO — A combination of Gilead Sciences’ Trodelvy and Merck’s Keytruda has demonstrated a significant reduction in tumor progression among women battling an aggressive form of breast cancer.
- The Phase 3 ASCENT-04 study,a randomized trial,revealed results that could pave the way for a new treatment strategy for patients with newly diagnosed,metastatic,triple-negative breast cancer.
- Gilead Sciences,which spearheaded the study,stands to gain from increased Trodelvy sales.
Early results from a groundbreaking study suggest a powerful combination therapy could revolutionize treatment for metastatic, triple-negative breast cancer. Gilead Sciences and Merck have teamed up,and the results are promising,as the combined treatment reduced tumor progression risk by over 33%. The Phase 3 ASCENT-04 trial provides critical data that highlights a potential new standard of care for women facing this aggressive form of cancer. This development, reported by News Directory 3, offers hope to patients and signals a shift in treatment strategies, potentially boosting sales for those involved, although they compete with AstraZeneca and Daiichi sankyo.Discover what’s next for this innovative breast cancer treatment.
Gilead, Merck Combo Shows Promise in Triple-Negative Breast Cancer Treatment
Updated May 31, 2025
CHICAGO — A combination of Gilead Sciences’ Trodelvy and Merck’s Keytruda has demonstrated a significant reduction in tumor progression among women battling an aggressive form of breast cancer. The treatment, combining two distinct cancer-fighting medicines, decreased the risk by more than one-third.
The Phase 3 ASCENT-04 study,a randomized trial,revealed results that could pave the way for a new treatment strategy for patients with newly diagnosed,metastatic,triple-negative breast cancer. Experts suggest this combination offers a potential advancement in care.
Gilead Sciences,which spearheaded the study,stands to gain from increased Trodelvy sales. The drug faces growing competition from similar treatments developed by AstraZeneca and Daiichi Sankyo.
What’s next
Further research is anticipated to explore the long-term benefits and potential applications of this combination therapy in treating metastatic, triple-negative breast cancer.